The U.S. Food and Drug Administration is piloting “real-time clinical trials” (RTCTs) that stream endpoint and signal information as studies run, aiming to shorten the lag between first data and regulatory decisions. The FDA said it initiated RTCT pilots with AstraZeneca and Amgen and validated its technical framework, including signal reporting through Paradigm Health for the AstraZeneca study.